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The ErbB family of transmembrane receptors has four members,
namely epidermal growth factor receptor (EGFR)/HER1/ErbB1, HER2/
ErbB2, HER3/ErbB3 and HER4/ErbB4 [1]. Each member is a typical
receptor tyrosine kinase, comprising an extracellular ligand binding
region, a single membrane-spanning region, and a cytoplasmic
C-terminal region that contains the tyrosine kinase domain. ErbB
receptors control intracellular signaling pathways that govern
fundamental cellular processes, including proliferation, migration,
metabolism and survival. They therefore have important roles during
development and in normal adult physiology [2]. In addition, EGFR
and HER2 have been implicated in the pathogenesis of several types of
human cancer [3]. For example, HER2 is overexpressed in 20–25% of
invasive breast cancers [4], and increased HER2 expression correlates
strongly with a shorter time to relapse and a decrease in overall
survival [5].Unlike other members of the ErbB family, HER2 does not bind a
speciﬁc ligand directly. Instead, it exists in a constitutively phosphor-
ylated state [6,7]. Active HER2 forms protein–protein complexes with
a diverse array of intracellular signaling molecules and, through these
interactions, stimulates the phosphatidylinositol 3-kinase (PI3K)/AKT
andmitogen-activated protein kinase (MAPK) cascades [8]. Activation
of these pathways downstream of HER2 results in increased cell
proliferation, transformation and oncogenesis [8]. Recently, increas-
ing effort has been directed towards identifying methods to overcome
HER2-stimulated carcinogenic signaling. Evidence suggests that the
intracellular proteins to which HER2 binds are, at least in part,
responsible for its transforming ability [8,9]. Manipulation of the
interactions between HER2 and these targets therefore holds
potential for anti-cancer therapy [9]. For speciﬁc manipulation to
become possible, the region(s) on HER2 to which each protein binds
must be accurately identiﬁed.
Calmodulin (CaM) is a small Ca2+ binding protein that interacts
with multiple intracellular targets. Although the best characterized of
these are the serine/threonine kinases [10], a large body of literature
has revealed several “non-classic” CaM binding partners [11]. The
discovery of these proteins, which include cell surface receptors such as
the insulin receptor [12,13], steroid receptors such as estrogen receptor
α (ERα) [14–16], and ion channels such as the Ca2+-gated K+ channel
[17], has substantially increased the number of physiological and
pathological processes known to be regulated by CaM. Of particular
interest is the fundamental role CaM now appears to play in breast
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stimulates tumorigenesis in ER(+) breast carcinoma [18]), and
tamoxifen, a triphenylethylenic antiestrogen used for the treatment
of steroid receptor-positive breast cancer [19], modulates CaM–ERα
binding [14,16,20].
CaM is known to interact with ErbB family members. Initial
analyses suggested that the cytosolic juxtamembrane region of EGFR,
speciﬁcally residues 645–660, regulated Ca2+-dependent CaM bind-
ing [21]. Later reports conﬁrmed these ﬁndings [22,23], and deletion
of this region was shown to result in a mutant receptor with no
detectable EGF-stimulated kinase activity despite an intact ligand
binding capacity [24–26]. One study suggested that CaM also binds
HER2 [27], but this observation has not been independently validated.
Moreover, the region of HER2 with which CaM interacts and the
functional consequences of CaM binding on HER2-stimulated tumor-
igenesis remain undeﬁned. Here, we identify the CaM binding sites on
HER2, and show that antagonizing CaM function or disrupting CaM–
HER2 association inhibits both HER2 phosphorylation and HER2-
stimulated cell growth. Collectively, these data suggest that inhibition
of CaM–HER2 interaction may be a potential approach for treating
patients with breast cancer.
2. Materials and methods
2.1. Materials
SkBR3 and HEK293 cells were obtained from the American Type
Culture Collection (Manassas, VA). All tissue culture reagents were
obtained from Gibco (Carlsbad, CA). Anti-phospho-HER2 (Tyr1221/
Tyr1222), anti-HER2 and anti-β-Tubulin antibodies, and a glutathione
S-transferase (GST) fusion construct encoding the entire HER2
intracellular domain (designated GST-HER2; residues 676–1255
[numbering corresponds to the immature sequence]) were obtained
from Cell Signaling Technology (Danvers, MA). CaM–Sepharose and
secondary antibodies for enhanced chemiluminescence (ECL) detec-
tion were obtained from GE Healthcare (Piscataway, NJ). Pure CaM
was obtained from Ocean Biologics (Edmonds, WA). The highly
speciﬁc anti-CaM monoclonal antibody has been previously charac-
terized [28]. CGS9343B was obtained from Tocris Biosciences
(Ellisville, MO). Unless otherwise stated, all other reagents were of
standard analytical grade.
2.2. Preparation of constructs and fusion proteins
GST-HER2 was expressed in Escherichia coli and isolated using
glutathione-Sepharose essentially as previously described [29]. To
construct GST-HER-N, GST-HER2-M, GST-HER2-C and GST-HER2Δ1,
PCR was performed using GST-HER2 as a template with the following
primers: GST-HER2-N: 5′-GAAGATCTAAGCGACGGCAGCAGAAGATCC-
3′ (F), 5′-GCTCTAGACTCGAGTCACCGACATTCAGAGTCAATC-3′
(R); GST-HER2-M: 5′-GAAGATCTGACCTGCTGAACTGGTGTATGC-3′
(F), 5′-GCTCTAGACTCGAGTCACTGTAGAGGGCTGGGGTCATG-3′ (R);
GST-HER2-C: 5′-GAAGATCTCCAAGATTCCGGGAGTTGGTG-3′ (F), 5′-
GCTCTAGACTCGAGTCACACTGGCACGTCCAGACCC-3′ (R); GST-
HER2Δ1: 5′-GAAGATCTCTGCTGCAGGAAACGGAGC-3′ (F), 5′-GCTCTA-
GACTCGAGTCACCGACATTCAGAGTCAATC-3′ (R). All forward primers
included the BGLII restriction site and all reverse primers included the
XhoI restriction site. The product was cut with BGLII and XhoI and
subcloned into the BGLII–XhoI restriction sites of pGEX4T-1. To construct
GST-HER2Δ2andGST-HER2Δ3, PCRwasperformedusingGST-HER2-Nas
a template with the following primers: GST-HER2Δ2: 5′-phos-ACAGTC-
TACAAGGGCATCTGG-3′ (F), 5′-phos-CCGCATCTGCGCCTGGTTGGG-3′
(R); GST-HER2Δ3: 5′-phos-AGTGATGTGTGGAGTTATGGTG-3′ (F), 5′-
phos-CCCATCTGCATGGTACTCTGTC-3′ (R). GST-HER2Δ1,3 and GST-
HER2Δ1,2,3 were constructed using sequential PCR reactions and
appropriate template with the primers listed above. To construct GST-HER2-1, PCR was performed to anneal the following primers: 5′-
GATCTAAGCGACGGCAGCAGAAGATCCGGAAGTACACGATGCGGAGAT
GAG-3 ′ (F ) , 5 ′ -AATTCTCATCTCCGCATCGTGTACTTCCG-
GATCTTCTGCTGCCGTCGCTTA-3′ (R). GST-HER-1,2, GST-HER2-2 and
GST-HER2-3 were constructed using PCR with pcDNA3-HER2 as a
template and the following primers: GST-HER2-1,2: 5′-GAAGATCTAAGC-
GACGGCAGCAGAAGATCC-3′ (F), 5′-CGGAATTCTCAGCCAAAAGCGCCA-
GATCC-3′ (R); GST-HER2-2: 5′-GAAGATCTATCCTGAAAGAGACGGAG-3′
(F), 5′-CGGAATTCTCAGCCAAAAGCGCCAGATCC-3′ (R); GST-HER2-3: 5′-
GAAGATCTGGCAAGGTGCCCATC-3′ (F), 5′-CGGAATTCTCACTGGTGGGT-
GAACCG-3′ (R). All forward primers included the BglII restriction site and
all reverse primers included the EcorI restriction site. The product was
cut with BglII and EcorI and subcloned into the BamHI–EcorI restriction
sites of pGEX4T-1. To construct full-length HER2Δ1 and full-length
HER2Δ2 (designated HER2Δ1FL and HER2Δ2FL, respectively), pBLUE-
SCRIPT-II-HER2Δ1 and pBLUESCRIPT-II-HER2Δ2, respectfully, were cut
with EcorI and the product was subcloned into the EcorI restriction
sites of pcDNA3-HER2. Prior to their inclusion in experiments, the
sequences of all constructs were conﬁrmed by dye-terminator
sequencing.
2.3. In vitro binding assays
For in vitro binding experiments using pure proteins, pure CaM
was incubated with pure GST-HER2 (residues 676–1255), GST-HER2-
N (residues 676–966), GST-HER2-M (residues 820–1110), GST-HER2-
C (residues 967–1255), GST-HER2Δ1 (residues 676–966 with resi-
dues 676–689 deleted), GST-HER2Δ2 (residues 676–966 with
residues 714–732 deleted), GST-HER2Δ3 (residues 676–966 with
residues 883–902 deleted), GST–HER2Δ1,3 (residues 676–966 with
residues 676–689 and 883–902 deleted), GST–HER2Δ1,2,3 (residues
676–966 with residues 676–689, 714–732 and 883–902 deleted),
GST–HER2-1 (residues 676–689), GST-HER2-1,2 (residues 676–732),
GST–HER2-2 (residues 714–732), GST–HER2-3 (residues 883–902)
(all N90% pure) or GST alone in 500 μl Ca2+ buffer (50 mM Tris (pH
7.4), 150 mM NaCl, 1 mM CaCl2 and 1% (v/v) Triton X-100) or EGTA
buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EGTA and 1% (v/v)
Triton X-100) for 3 h at 4 °C. GST-bound complexes were isolated
using glutathione-Sepharose beads, washed 6 times in the same
buffer used in the incubation, resolved by SDS-PAGE and processed by
Western blotting.
2.4. Cell culture and transfection
SkBR3 cells were maintained in McCoy's 5AMedium supplemented
with 10% (v/v) fetal bovine serum and 1% (v/v) penicillin/streptomycin.
HEK293 cells were maintained in Dulbecco's Modiﬁed Eagles Medium
supplemented with 10% (v/v) fetal bovine serum and 1% (v/v)
penicillin/streptomycin. Cultures were regularly conﬁrmed to be free
of mycoplasma contamination. Transfections were performed using
Trans-IT (Mirus, Madison, WI) according to the manufacturer's
instructions.
2.5. CaM–Sepharose pulldown assays
SkBR3 cells were plated in 100 mm dishes at a density of 5×106
cells/dish and allowed to attach overnight. The following day, cells
were washed twice with ice-cold phosphate-buffered saline (PBS)
and lysed in Ca2+ buffer or EGTA buffer supplemented with 10 μg/ml
aprotinin, 10 μg/ml leupeptin and 1 mM phenylmethylsulfonyl ﬂuo-
ride (together designated buffer C+ and E+, respectively). CaM–
Sepharose pull down assays were performed essentially as previously
described [30]. Brieﬂy, clariﬁed cell lysates were equalized for protein
concentration using the modiﬁed Bradford Assay (Bio-Rad Laborato-
ries, Hercules, CA), and equal amounts of protein were incubated with
CaM–Sepharose or GST alone in 500 μl buffer C+or E+for 3 h at 4 °C.
Fig. 1. CaM binds HER2 in a Ca2+-regulated manner. CaM–Sepharose (CaM) or GST
alone was incubated with equal amounts of protein from SkBR3 cell lysates in the
presence (Ca2+) or absence (EGTA) of Ca2+. Complexes were isolated and washed as
described in materials and methods. The samples were resolved by SDS-PAGE,
transferred to polyvinylidene ﬂuoride (PVDF) membrane and probed with anti-HER2
antibody. An aliquot of each sample (equivalent to 2% of the amount in each pulldown)
was also processed by Western blotting (Lysate). The data are representative of 5
independent experiments.
Fig. 2. Residues 676–966 of HER2 are necessary for CaM binding. A, Schematic
representation of HER2 constructs depicting the HER2 intracellular domain and HER2
intracellular domain fragments. The speciﬁc residues present in each fragment are
indicated. HER2, entire HER2 intracellular domain (residues 676–1255); HER2-N,
N-terminal portion of HER2 intracellular domain (residues 676–966); HER2-M, middle
fragment of HER2 intracellular domain (residues 820–1110); HER2-C, C-terminal
portion of HER2 intracellular domain (residues 967–1255). B, Pure GST-HER2, GST-
HER2-N, GST-HER2-M, GST-HER2-C or GST alone was incubated with equal amounts of
pure CaM in the presence (Ca2+) or absence (EGTA) of Ca2+. Complexes were isolated
and washed as described in the materials and methods and samples were resolved by
SDS-PAGE. After running, the gel was cut at the 50 kDa marker. The bottom half was
transferred to PVDF membrane and probed with anti-CaM antibody (Pulldown). The
top half was stained with Coommassie to demonstrate essentially equal amounts of
GST-HER2 in each sample (Coommassie). An aliquot of pure CaM (equivalent to 2% of
the amount in each pulldown) was also resolved by SDS-PAGE and processed as
described (Input). The data are representative of 5 independent experiments.
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washed 6 times in the same buffer used in the incubation, resolved by
SDS-PAGE and processed by Western blotting. GST-bound complexes
were isolated using glutathione-Sepharose beads and washed and
processed in the same way.
2.6. Measurement of HER2 phosphorylation and signaling
SkBR3 cells were plated in 6 well plates at a density of 2×105
cells/well and allowed to attach overnight. The following day, cells
were serum-starved in the presence of vehicle (DMSO) or 10 μM
CGS9343B for 48 h. HEK293 cells were plated in 6 well plates at a
density of 1×105 cells/well and allowed to attach overnight. The
following day, cells were transfected with 2.5 μg/well vector
(pcDNA3), HER2, HER2Δ1FL or HER2Δ2FL. 24 h after transfection,
cells were serum-starved for 48 h. For lysis, cell monolayers were
placed on ice, washed twice with ice-cold PBS and lysed in 50 μl/well
lysis buffer (50 mM Tris (pH 8.0), 100 mM NaF, 30 mM Na4P2O7,
2 mM Na2MoO4 and 2 mM Na3VO4) supplemented with 10 μg/ml
aprotinin, 10 μg/ml leupeptin and 1 mM phenylmethylsulfonyl
ﬂuoride. Clariﬁed cell lysates were equalized for protein concentra-
tion using the modiﬁed Bradford Assay, resolved by SDS-PAGE and
processed by Western blotting. HER2 phosphorylation was mea-
sured by probing blots with phospho-speciﬁc HER2 antibody
(dilution 1:1,000). In all experiments, blots were stripped by
incubating with stripping buffer (62.5 mM Tris (pH 6.8), 2% (w/v)
SDS and 0.7% (v/v) β-mercaptoethanol) for 30 min at 50 °C, then
reprobed with an antibody against total HER2 (dilution 1:1,000). All
blots were also probed with anti-β-Tubulin antibody (dilution
1:2,000) to verify protein loading. Densitometry was performed
using ImageJ (Version 1.43).
2.7. Measurement of HER2-stimulated cell growth
HER2-stimulated cell growth was measured using sulforhodamine
B staining essentially as previously described [31]. Brieﬂy, SkBR3 and
HEK293 cells were plated, transfected if appropriate, and serum-
starved as described in the previous paragraph. Cell monolayers were
then placed on ice and 1 ml ice-cold 25% (w/v) trichloroacetic acid
was added directly to the culture medium. Cells were left for 1 h at
4 °C prior to being stained with 0.4% (w/v) sulforhodamine B (in 1%
(v/v) acetic acid). Protein-bound dye was dissolved in 10 mMTris (pH
10.5) and absorbencies were read at 510 nm.
2.8. Statistical analysis
All experiments were repeated independently at least 3 times.
Statistical signiﬁcancewas set at pb0.05 and analyseswere performed
using the Student's t test. In all ﬁgures, * denotes statistical signiﬁcance
from control cells.
3. Results
3.1. CaM binds HER2 in a Ca2+-regulated manner
To determine whether CaM interacts with HER2 in a normal cell
milieu, we lysed SkBR3 cells, a malignant human breast epithelial cell
line that overexpresses HER2, and incubated the lysate with CaM–
Sepharose in the presence or absence of Ca2+. In the presence of Ca2+,
binding of endogenous HER2 in cell lysates to CaM–Sepharose is
readily detected (Fig. 1). Chelating Ca2+ with EGTA substantially
reduces, but does not abrogate, CaM–Sepharose–HER2 association.
The speciﬁcity of the interaction is validated by the absence of HER2
from samples that were incubated with GST alone (Fig. 1). The
amount of HER2 in all cell lysates was equivalent. These data reveal
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CaM and HER2.3.2. Identiﬁcation of the CaM binding domain on HER2
The region of HER2 to which CaM binds was initially investigated
using pure CaM and selected GST-tagged HER2 fragments (Fig. 2A).
CaM was incubated with GST-HER2 constructs and GST-bound
complexes were isolated, resolved by SDS-PAGE and processed by
Western blotting. Ca2+/CaM binds GST-HER2 but not GST alone
(Fig. 2B). Examination of 3 peptides spanning the entire intracellular
region of HER2 revealed that only the proximal N-terminal portion
(HER2-N; residues 676–966) binds Ca2+/CaM. No interaction be-
tween Ca2+/CaM and the middle fragment (HER2-M; residues 820–
1110) or the C-terminal portion (HER2-C; residues 967–1255) of
HER2 was detected. The amount of apocalmodulin (Ca2+-free CaM)
that binds HER2 and HER2-N is less than that of Ca2+/CaM (Fig. 2B).
As expected, no apocalmodulin binds HER2-M or HER2-C. The amount
of HER2 in each sample was essentially identical (Fig. 2B). Note that
GST alone is not visible in the Coommassie images as the gel was cut at
the 50 kDa marker and only the top half was stained. These data
suggest that the region of HER2 containing residues 676–966 is
necessary for binding both Ca2+/CaM and apocalmodulin.Fig. 3. The HER2 intracellular domain contains 3 putative CaM binding sites. The entire HE
calcium.uhnres.utoronto.ca/ctdb/ctdb/home.html). Three putative CaM binding domains
(underline) and HER2-C (blue) are shown.To narrow the CaM binding site, we analyzed the entire HER2
intracellular sequence using the Calmodulin Target Database (http://
calcium.uhnres.utoronto.ca/ctdb/ctdb/home.html) and found 3 puta-
tive CaM interacting regions (Fig. 3). To investigate whether each of
these sites is necessary for CaM–HER2 binding, we individually
deleted each region from GST-HER2-N (residues 676–966; Fig. 3 and
Fig. 4A). Deletion of either region 1 (HER2Δ1; residues 676–689
deleted) or 2 (HER2Δ2; residues 714–732 deleted) markedly
attenuates the interaction of Ca2+/CaM with HER2 (Fig. 4B). In
contrast, deletion of the third region (HER2Δ3; residues 883–902
deleted) does not alter Ca2+/CaM–HER2 binding. The last observation
is not surprising as region 3 is present in both HER2-N and HER2-M
(Fig. 3); HER2-M does not bind CaM (Fig. 2B). Deletion of regions 1
and 3 together (HER2Δ1,3; residues 676–689 and 883–902 deleted)
considerably reduces, but does not abrogate, binding of HER2 to Ca2+/
CaM. In contrast, deletion of regions 1, 2 and 3 together (HER2Δ1,2,3;
residues 676–689, 714–732 and 883–902 deleted) eliminates the
ability of Ca2+/CaM to associate with HER2.
In contrast to Ca2+/CaM, apocalmodulin fails to bind HER2Δ1
(Fig. 4B). Interestingly, deletion of residues 714–732 (HER2Δ2) does
not impair apocalmodulin binding. Binding of apocalmodulin to
HER2Δ2, HER2-N and HER2Δ3 was essentially the same (Fig. 4B).
Deletion of regions 1 and 3 together or 1, 2 and 3 together eliminates
association of apocalmodulin with HER2. The speciﬁcity of theR2 intracellular sequence was analyzed using the Calmodulin Target Database (http://
were identiﬁed (bold print). The regions corresponding to HER2-N (red), HER2-M
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incubated with HER2-C or GST alone (Fig. 4B). The amount of HER2 in
each sample was essentially identical (Fig. 4B). These data strongly
suggest that residues 676–689 (KRRQQKIRKYTMRR) and 714–732
(ILKETELRKVKVLGSGAFG) of HER2 are necessary for its interaction
with Ca2+/CaM, while residues 676–689 of HER2 comprise the
apocalmodulin binding region.
To conﬁrm that the CaM-binding regions of HER2 we identiﬁed are
sufﬁcient tomodulate its associationwith CaM,we created GST-fusion
proteins of each site and evaluated the interaction with CaM. CaMwas
incubated with each peptide and GST-bound complexes were
isolated, resolved by SDS-PAGE and processed by Western blotting.
HER2-1 (residues 676–689) and HER2-2 (residues 714–732) bind
essentially the same amount of Ca2+/CaM, while no Ca2+/CaM binds
to HER2-3 (residues 883–902; Fig. 4C). The amount of Ca2+/CaM
bound to HER2-1,2 (residues 676–732) was substantially greater than
that of either HER2-1 or HER2-2. HER2-1 and HER2-1,2 bind
equivalent amounts of apocalmodulin, while no apocalmodulin
binds to HER2-2 or HER2-3 (Fig. 4C). The speciﬁcity of the interaction
is validated by the absence of CaM from samples that were incubated
with GST alone. The amount of GST-fusion protein in each sample was
essentially identical (Fig. 4C). These data indicate that residues 676–
689 and 714–732 of HER2 are sufﬁcient tomediate its interactionwith
Ca2+/CaM, and imply a synergistic effect of the two binding regions.
Residues 676–689 are sufﬁcient for HER2-apocalmodulin binding.
3.3. CaM modulates HER2 phosphorylation
We employed a complimentary loss/gain of function strategy to
ascertain the biological relevance of the CaM–HER2 interaction. For
loss of function analysis, SkBR3 cells were treated with either vehicle
or the speciﬁc cell-permeable CaM antagonist CGS9343B [32]. In
parallel, HEK293 cells were transfected with vector (pcDNA3), HER2,
or HER2 lacking the CaM binding regions. These constructs are termed
HER2Δ1FL (residues 676–689 deleted) and HER2Δ2FL (residues 714–
732 deleted). HER2 phosphorylation was evaluated by Western
blotting. Inhibition of CaM function reduces HER2 phosphorylation
in SkBR3 cells by ~70% (Fig. 5A; Fig. 5B, left panel). No signiﬁcantFig. 4. Residues 676–689 and 714–732 of HER2 are necessary for CaM binding.
A, Schematic representation of HER2 constructs depicting HER2 intracellular domain
fragments and HER2 intracellular domain deletion mutants. The speciﬁc residues
present in each fragment as well as those removed from each deletion mutant are
indicated. HER2-N, N-terminal portion of HER2 intracellular domain (residues 676–
966); HER2Δ1, N-terminal portion of HER2 intracellular domain with residues 676–689
deleted; HER2Δ2, N-terminal portion of HER2 intracellular domain with residues 714–
732 deleted; HER2Δ3, N-terminal portion of HER2 intracellular domain with residues
883–902 deleted; HER2Δ1,3, N-terminal portion of HER2 intracellular domain with
residues 676–689 and 883–902 deleted; HER2Δ1,2,3, N-terminal portion of HER2
intracellular domain with residues 676–689, 714–732 and 883–902 deleted; HER2-C,
C-terminal portion of HER2 intracellular domain (residues 967–1255). B, Pure GST-
HER2-N, GST-HER2Δ1, GST-HER2Δ2, GST-HER2Δ3, GST-HER2Δ1,3, GST-HER2Δ1,2,3,
GST-HER2-C or GST alone was incubated with equal amounts of pure CaM in the
presence (Ca2+) or absence (EGTA) of Ca2+. Complexes were isolated and washed as
described in materials and methods and samples were resolved by SDS-PAGE. After
running, the gel was cut at the 50 kDa marker. The bottom half was transferred to PVDF
membrane and probed with anti-CaM antibody (Pulldown). The top half was stained
with Coomassie to demonstrate essentially equal amounts of GST-HER2 in each sample
(Coomassie). An aliquot of pure CaM (equivalent to 2% of the amount in each pulldown)
was also resolved by SDS-PAGE and processed as described (Input). The data are
representative of 5 independent experiments. C, Pure GST–HER2-1, GST–HER2-1,2,
GST–HER2-2, GST–HER2-3 or GST alone was incubated with equal amounts of pure
CaM in the presence (Ca2+) or absence (EGTA) of Ca2+. Complexes were isolated and
washed as described in the materials and methods and samples were resolved by SDS-
PAGE. After running, the gel was cut at the 20 kDa marker. The bottom half was
transferred to PVDF membrane and probed with anti-CaM antibody (Pulldown). The
top half was stained with Coomassie to demonstrate essentially equal amounts of
peptide in each sample (Coomassie). An aliquot of pure CaM (equivalent to 2% of the
amount in each pulldown) was also resolved by SDS-PAGE and processed as described
(Input). The data are representative of 3 independent experiments.
Fig. 5. CaM is necessary for HER2 phosphorylation. A, SkBR3 cells were serum-starved in the presence of vehicle (DMSO) or 10 μMCGS9343B for 48 h. Equal amounts of protein were
resolved by SDS-PAGE, transferred to PVDF membrane and probed with anti-phospho-HER2, anti-HER2 and anti-β-Tubulin antibodies. The data are representative of 5 independent
experiments. B, The amount of phospho-HER2was quantiﬁed by densitometry and corrected for the amount of HER2 in the corresponding lysate. The amount of HER2was quantiﬁed
by densitometry and corrected for the amount of β-Tubulin in the corresponding lysate. The data, expressed relative to the amount of each protein in cells treated with DMSO (black
bars), represent the mean±SE (n=5). *pb0.05. C, HEK293 cells were transfected with vector (pcDNA3), HER2, HER2Δ1FL or HER2Δ2FL prior to being serum-starved for 48 h. Equal
amounts of protein were resolved by SDS-PAGE, transferred to PVDF membrane and probed with anti-phospho-HER2, anti-HER2 and anti-β-Tubulin antibodies. The data are
representative of 3 independent experiments.
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compared to cells treated with DMSO only (data not shown).
Moreover, neither DMSO nor CGS9343B signiﬁcantly reduces the
total amount of HER2 (Fig. 5A; Fig. 5B, right panel) or β-Tubulin
(Fig. 5A). In HEK293 cells, transfection of HER2 resulted in a clearly
detectable phosphorylation band (Fig. 5C). By contrast, no phospho-
HER2 was detected in cells transfected HER2Δ1FL or HER2Δ2FL. Note
that the expression of HER2, HERΔ1FL and HER2Δ2FL was essentially
identical (Fig. 5C). Together, these data indicate that CaM binding to
HER2 is necessary for HER2 phosphorylation.
3.4. CaM binding to HER2 is necessary for HER2-stimulated cell growth
In HER2(+) breast tumors, aberrant HER2 phosphorylation
stimulates cell cycle progression and uncontrolled cell proliferation
[8]. To ascertain whether CaM modulates HER2 function, we
measured HER2-stimulated cell growth under two different condi-
tions. The CaM antagonist CGS9343B signiﬁcantly inhibits prolifera-
tion of SkBR3 cells by ~30% (Fig. 6). Neither CGS9343B nor DMSO
signiﬁcantly affects cell viability (as determined by trypan blueexclusion; data not shown). CaM modulates multiple enzymes,
several of which could be suppressed by CGS9343B treatment.
Therefore, we tested the speciﬁc effect of CaM on HER2-stimulated
cell growth by examining the effect of mutant HER2 constructs that
lack binding to CaM. In HEK293 cells, transfection of HER2 increases
cell growth by ~30% (Fig. 6B). In contrast, neither HER2Δ1FL nor
HER2Δ2FL have any signiﬁcant effect. These data indicate that CaM
binding to HER2 is necessary for HER2 to stimulate cell growth.
4. Discussion
The functional interaction of CaM with EGFR has been the focus of
investigations by several groups (reviewed in reference [33]). In
contrast, despite the incontrovertible clinical importance of HER2,
only one study has explored CaM–HER2 association [27]. Moreover,
neither the region of HER2 with which CaM interacts nor the effect of
CaM on HER2-stimulated tumorigenesis has been evaluated. Here, we
show that CaM binds, in a Ca2+-regulated manner, to two distinct
sites on the N-terminal portion of the HER2 intracellular domain.
Deletion of residues 676–689 and 714–732 fromHER2 prevented CaM
AB
Fig. 6. CaM is necessary for HER2-stimulated cell growth. A, SkBR3 cells were serum-
starved in the presence of vehicle (DMSO) or 10 μMCGS9343B for 48 h. Cell growthwas
measured using sulforhodamine B staining. The data, expressed relative to the number
of cells in wells treated with DMSO (black bars), represent the mean±SE (n=5).
*, pb0.05. B, HEK293 cells were transfected with vector (pcDNA3), HER2, HER2Δ1FL or
HER2Δ2FL prior to being serum-starved for 48 h. Cell growth was measured using
sulforhodamine B staining. The data, expressed relative to the number of cells in wells
transfected with vector (pcDNA3; black bars), represent the mean±SE (n=3).
*, pb0.05.
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interaction reduced HER2 phosphorylation and HER2-stimulated cell
growth. Collectively, these data suggest that manipulation of CaM–
HER2 binding may be a feasible approach to treat patients with breast
cancer.
Our data reveal that HER2 binds both Ca2+/CaMand apocalmodulin.
Although binding is considerably reduced in the absence of Ca2+,
analysis with both pure proteins and breast epithelial cell lysates
consistently detected a speciﬁc interaction between apocalmodulin and
HER2. These ﬁndings are in contrast to a prior report which observed an
association between CaM and HER2 only in the presence of Ca2+ [27].
Several factors may account for these discrepant data. For example,
while both studies evaluated binding of CaM immobilized on beads to
HER2 in the SkBR3 cell line, different buffers were used to lyse the cells.
Moreover, we examined binding of pure CaM and GST-HER2 to
substantiate our CaM–Sepharose data. In contrast, the prior publication
immunoprecipitatedHER2andusedoverlaywithbiotinylatedCaM[27].
It is possible that the tertiary conformation adopted by HER2EGFR 645 
HER2 676 KRRQQKIRKYTMRRLLQETELVEPLTPSGA
Fig. 7. Sequence alignment of the juxtamembrane portion of EGFR and HER2. Conserved res
shown (bold print).immobilized on a membrane may sterically obscure the binding region
for apocalmodulin, while permitting an association with Ca2+/CaM.
The CaM binding regions of target proteins do not show strong
sequence homology [34]. Nevertheless, two general characteristics
may be observed. Many Ca2+/CaM binding proteins have an
amphipathic helix (comprising approximately 20 residues) that
contains hydrophobic and basic amino acids [10]. Another CaM
binding domain, termed the IQ motif, binds CaM in a predominantly
Ca2+-independent manner. The IQ motif generally comprises the
sequence IQxxxRGxxxR (where x denotes any amino acid), however
Ile1 and Gly7 are frequently not conserved [35]. Inspection of residues
676–689 of HER2 reveals a putative IQ motif: KRRQQKIRKYTMRR (the
underlined residues comprise the IQ domain). Consistent with this in
silico analysis, deletion of residues 676–689 prevents apocalmodulin
from binding HER2. In contrast, deletion of the second putative CaM
binding domain, residues 714–732, has no signiﬁcant effect on
apocalmodulin-HER2 association. These data are substantiated by
our ﬁndingswhich reveal that residues 676–689 of HER2 are sufﬁcient
for apocalmodulin interaction, while residues 714–732 are unable to
modulate apocalmodulin-HER2 binding. Together, these observations
suggest that residues 676–689 represent the region of HER2 with
which CaM interacts in a Ca2+-independent manner.
Our ﬁndings with Ca2+/CaM were different from those with
apocalmodulin. Elimination of residues 676–689 from HER2markedly
attenuates, but does not abrogate, its interaction with Ca2+/CaM,
implying the existence of a second CaM binding region. Moreover,
deletion of residues 714–732 (ILKETELRKVKVLGSGAFG) considerably
reduces Ca2+/CaM association with HER2, suggesting that this region
is also necessary for Ca2+/CaM interaction. Consistent with this
observation, deletion of both regions 676–689 and 714–732 elim-
inates Ca2+/CaM–HER2 binding. It is important to emphasize that we
cannot exclude the possibility that the deletions we made alter the
tertiary conformation of HER2. Nevertheless, our ﬁndings are
supported by our analyses using synthesized peptides, which
demonstrate that both residues 676–689 and residues 714–732 of
HER2 interact with Ca2+/CaM.
The interaction between CaM and EGFR has been characterized in
some detail. CaM binds to the cytosolic juxtamembrane region of
EGFR, amino acids 645–660 [23,36,37]. Sequence alignment reveals
that this domain is similar to that of residues 676–689 of HER2
(Fig. 7). Although no other CaM binding region has been identiﬁed on
EGFR, residues 714–732 of HER2 (the second CaM interacting region)
exhibit 84% homology to the corresponding EGFR residues (Ile682–
Gly700; Fig. 7). Unfortunately, no published study has analyzed the
possible role of this domain in CaM–EGFR interaction. Each report that
concluded that the juxtamembrane region of EGFR mediates its
interaction with CaM analyzed only the juxtamembrane domain
(which terminates at Phe688) [23,36,37]. The region of EGFR
corresponding to the second CaM binding domain of HER2 terminates
at Gly700. Several CaM targets, including other receptors, have more
than one CaM binding site [38,39]. It therefore remains possible that
CaM may associate with EGFR at a site distal to the juxtamembrane
region.
ErbB receptor activity is regulated by autophosphorylation of
tyrosine residues within the activation loop of the kinase domain
[40,41], therefore HER2 catalytic activity may be measured by
quantifying HER2 phosphorylation [42]. We report here that inhibi-
tion of CaM function with CGS9343B markedly reduces HER2703 
MPNQAQMRILKETELRKVKVLGSGAFGTVY 735  
idues are highlighted in yellow. The amino acids deleted from HER2Δ1 and HER2Δ2 are
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activation. These data are supported by our observations which reveal
that deletion of either CaM binding site from HER2 abrogates HER2
phosphorylation, and by a previous study which demonstrated that
incubation of SkBR3 cells with the CaM antagonist W7 prevents HER2
phosphorylation in response to heregulin [27]. In HER2(+) breast
neoplasms, aberrant HER2 phosphorylation stimulates uncontrolled
cell proliferation and, consequently, rapid tumor growth [8]. Perhaps
the most important ﬁnding to come from this study is, therefore, our
observation that antagonism of CaM function or disruption of CaM–
HER2 association signiﬁcantly reduces HER2-stimulated cell growth.
It is likely that this inhibition arises as a direct result of the effect of
CaM on HER2 phosphorylation. In vitro studies have conﬁrmed a
direct link between decreased cell growth and reduced HER2
phosphorylation and signaling [43,44]. Furthermore, these reports
have been validated in both animal models [45,46] and clinical
investigations of primary human neoplasms [47,48].
In conclusion, we report both in vitro and in intact cells that CaM
associates with HER2 in a Ca2+-regulated, but not exclusively Ca2+-
dependent, manner. More importantly, we document a role for CaM in
HER2 phosphorylation, and reveal a previously unrecognized function
of CaM in HER2-stimulated tumorigenesis. When viewed in conjunc-
tion with prior observations that CaM antagonists augment anti-
estrogen therapy [49], our ﬁndings have potential implications for the
design of selectively targeted small molecule inhibitors for the
treatment of breast cancer.
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